Endo acquires NuPathe for $105 million
MALVERN, Pa. – Endo Health Solutions will acquire the maker of a patch used to treat migraines that received Food and Drug Administration approval at the beginning of this year.
Endo said Monday that it would buy NuPathe for $105 million. In January, the FDA approved NuPathe’s patch, Zecuity, a disposable, single-use, battery-powered transdermal patch that delivers the drug sumatriptan, the most widely prescribed migraine medication.
"The acquisition of NuPathe enhances our branded pharmaceutical portfolio and is well-aligned with our strategy of acquiring late-stage products for commercialization," said Endo president and CEO Rajiv De Silva. "We’re excited about the opportunity to launch Zecuity, a treatment that could be an option for millions of migraine patients, including those with migraine-related nausea."
Everett Labs acquires Quinnova Pharmaceuticals from Amneal Enterprises
CHATHAM, N.J. — Everett Labs has acquired Quinnova Pharmaceuticals from Amneal Enterprises, Everett said Monday.
Everett Labs, a subsidiary of Spain-based Exeltis, said the purchase would help it expand into the U.S. dermatology and women’s health markets. Financial terms of the deal were not disclosed.
"We believe dermatology is a very attractive opportunity for Everett in the U.S. market, and after an extensive search, we found Quinnova to be a great organization to help us grow this business," Everett Labs CEO Lucas Sigman said. "Quinnova offers important synergies for Everett with its innovative and entrepreneurial culture, as well as its dedicated and focused sales team, which is similar to Everett."
Valeant buys Solta Medical
LAVAL, Quebec — Valeant Pharmaceuticals International will acquire Solta Medical for about $250 million, Valeant said Monday.
The Canadian drug maker said the $2.92-per-share acquisition represented a 40% premium over Solta’s closing share price on Friday. Solta develops, manufactures and markets energy-based medical device systems for such cosmetic medical procedures as skin tightening, improving skin texture and others.
"The acquisition of Solta will bring tremendous value to Valeant’s current aesthetic and, together with our previous acquisitions, will create the broadest aesthetic portfolio in the industry," Valeant chairman and CEO J. Michael Pearson said. "Solta’s leading aesthetic devices are a natural fit with Valeant’s facial injectables, professional skin care products and physician-dispensed products, and will establish Valeant in a strong leadership position as we continue to build our presence in the aesthetic market."